Biotech Betting on Weight Loss Drugs | Business and Finance News

The biotech obesity drug race is a high-stakes gamble where only a handful of companies survive—each trial result can make or break a stock, with winners like Viking Therapeutics soaring 500% and losers like Skye Bioscience losing nearly everything. Years-long trials demand constant funding, forcing companies to dilute shares or risk collapse. Even without a drug to market, firms like a psychedelic developer can still cash out via big buyouts. For most investors, the safer play? A diversified biotech ETF. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a9cb5ef50d046f20